Signed and dated informed consent form (either by subject or LAR)
Willingness and ability to comply with all study procedures
Age 55 to 89 years, inclusive
Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis
Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits
Stable dose of Alzheimer's disease medications (e.g., donepezil, rivastigmine, memantine, galantamine) for at least 4 weeks prior to enrollment, if applicable
You may not be if
Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.)
History of Seizures
If patient holds neuroimaging showing space-occupying lesions
If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages
Current pregnancy or lactation (although unlikely in this population)
Participation in another clinical trial or investigational drug within the past 30 days
Active use of illicit substances or non-prescribed psychoactive drugs within the past 30 days.
Severe dementia due to Alzheimer's disease or another etiology
Physical or mental impairment that prevents the participant from complying with the cognitive testing battery.
